2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Renal Cell
11
Colorectal Neoplasms
4
Breast Neoplasms
3
Solid Tumors
2
Sarcoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Vulvar Neoplasms
1
Triple Negative Breast Neoplasms
1
Recurrence
1
Neuroendocrine Tumors
1
Neoplasms
1
Liver Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioblastoma
1
Gallbladder Neoplasms
1
Disease Progression
1
Disease
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Advanced Adult Hepatocellular Carcinoma
1
Interventions
Paclitaxel
115
Carboplatin
114
Cisplatin
46
Topotecan
43
Gemcitabine
31
Cyclophosphamide
31
Docetaxel
28
Bevacizumab
28
liposomal doxorubicin
27
Filgrastim
20
pembrolizumab
19
Peripheral Blood Stem Cell Transplantation
18
Taxes
15
Drug Therapy
15
Hyperthermic Intraperitoneal Chemotherapy
13
sargramostim
12
olaparib
12
Immunohistochemistry
11
Chemotherapy, Adjuvant
11
Surgical Procedures, Operative
10
Therapeutics
9
Flow Cytometry
9
Etoposide
9
oregovomab
8
niraparib
8
mirvetuximab soravtansine
8
Psychiatric Rehabilitation
8
Nivolumab
8
Amifostine
8
rucaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
tivozanib
×
Clear all
NCT01853644
2021-10-12
TIVO
Northwestern University
Phase 2
Completed
31 enrolled
12 charts